0350 GMT - UltraGreen.ai is unlikely to be weighed by the Trump administration's decision to impose a 100% tariff on patented pharmaceutical products, say DBS Group Research analysts in a note. The water-soluble, FDA-approved dye used by UltraGreen.ai for fluorescence imaging is considered a generic drug and falls under the current exemption, they say. Demand is likely to remain relatively price-inelastic even if the tariff regime is extended to include generics, and the company should be able to pass on any tariff-related costs to customers, they add. UltraGreen.ai's kits for the Americas are packaged in Michigan, which could be an additional mitigating factor against potential tariffs, the analysts say. DBS maintains its buy rating and US$2.00 target price. Shares are up 0.7% at US$1.44.(megan.cheah@wsj.com)

(END) Dow Jones Newswires

April 06, 2026 23:50 ET (03:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.